skip to Global Navigation Bar
skip to main content
HOME
CONTACT US
SITEMAP
KOREAN
Global Business
Introduction
Strategy
Manufacturing
Contact Us
R&D
Introduction
Global R&D Centers
R&D Organization
Pipeline
CDMO
Introduction
Manufacturing Sites
Business Model
Service Range
Products
Global Brand
Products Search
In-License
Introduction
Strategy
No.1 Position
Core-Competency
Licensed Products
Partnership
Investors
Management information
Financial information
Stock condition
IR information
About Us
Company Profile
CEO Message
Recruitment
Press Release
Company Profile
CEO Message
Recruitment
Press Release
News
PR Video
Home > About Us > Press Release >
News
뉴스
No
Subject
Data
265
Daewoong Pharmaceutical’s ‘NABOTA’ becomes the first Korea-made Botulinum Toxin to obtain US FDA approval
2019-02-02
264
Daewoong’s Hyangnam Plant acquires International Standard ISO 45001 (Safety & Health Management Systems)
2019-01-25
263
Daewoong Pharmaceutical Sets Standard for Global Drug Safety Reporting with Oracle
2019-01-17
262
Daewoong’s ‘NABOTA’ submitted the form to change clinical test plans in China.
2019-01-07
261
DAEWOONG Pharmaceutical’s New Year’s greetings: “The year 2019 will be the first year of our challenge to be a global healthcare group”
2019-01-02
260
Daewoong Pharmaceutical signs export contract to New Zealand and Israel with Nabota
2018-12-20
259
Daewoong Pharmaceutical enters into new drug candidate ‘BBT-401’ joint development and technology transfer contract with Bridgebio
2018-12-19
258
Daewoong Pharmaceutical attended ICAD 2018 and promoted benefit of Nabota
2018-11-27
257
Daewoong Pharmaceutical held NABOTA Symposium to commemorate first ever permit in advanced nation for domestic botulinum toxin
2018-11-20
256
Daewoong Pharmaceutical presented its vision and R&D capacity at the ‘5th China Healthcare Summit’
2018-11-16
1
/
2
/
3
/
4
/
5
/
6
/
7
/
8
/
9
/
10
/
News Search
subject
content
Home > About Us > Press Release > News
Home > About Us > Press Release > News